Anavex Reports Fiscal Second Quarter 2015 Financial Results

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Anavex Reports Fiscal Second Quarter 2015 Financial Results

NEW YORK, May 15, 2015 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. ("Anavex" or the "Company") (OTCQX:AVXL), a clinical-stage biopharmaceutical company developing drug candidates to treat Alzheimer's disease, other central nervous system (CNS) diseases, pain and various types of cancer, today reported financial results for the three and six months ended March 31, 2015.

Financial Highlights:

  • Anavex had cash and cash equivalents of approximately $6.3 million as of March 31, 2015, compared with approximately $7.0 million as at December 31, 2014. Cash was used in operations and for the advancement of clinical trial work. The Company has sufficient cash for approximately two years and intends to use the majority to complete the ongoing Phase 2a clinical trial of ANAVEX 2-73 and ANAVEX PLUS.  
  • Operating expenses for the second quarter of fiscal year 2015 were approximately $0.8 million, compared to approximately $1.0 million for the quarter ended March 31, 2014. The decrease was primarily attributable to the one-time, non-cash charges during the comparative three-month period ended March 31, 2014. This was offset by an increase in research and development expenses in the current period, primarily related to the ongoing Phase 2a clinical trial of ANAVEX 2-73 and ANAVEX PLUS.  
  • The net loss for the second quarter of fiscal year 2015 was approximately $1.7 million or $0.03 per share, compared to net loss of approximately $1.0 million or $0.03 per share for the same period in 2014. The increased loss was primarily attributable to the non-cash charges during the current three-month period ended March 31, 2015.

"Our team has made exceptional progress to date in advancing both our clinical and business strategies," said Christopher U. Missling, PhD, President and Chief Executive Officer of Anavex. "The Phase 2a clinical trial of ANAVEX 2-73 and ANAVEX PLUS continues to progress, with preliminary data expected around the Q3 timeframe. We are excited by the potential of ANAVEX 2-73 as a potential platform drug for multiple neurodegenerative diseases beyond Alzheimer's and by our other advancing pipeline products in CNS as well as pain and cancer."

Recent Achievements

On April 23, 2015, Dr. Missling presented at the World Orphan Drug Congress in Washington, D.C. He discussed the role of sigma-1 receptors in additional indications beyond Alzheimer's disease. The Company stated that, in parallel with the ongoing Alzheimer's trial of ANAVEX 2-73 and ANAVEX PLUS, it is able to expand the development of ANAVEX 2-73 into rare or orphan CNS diseases. 

On April 7, 2015, Anavex said it was encouraged by the findings of a new report in the latest issue of peer-reviewed scientific journal Neuroscience Letters . The study showed for the first time through real-time in vivo imaging how microglial inflammation, which is involved in devastating neurodegenerative diseases, can be resolved by sigma-1 receptor activation. The report underscored the potential therapeutic application of proprietary Anavex compounds in multiple neurological diseases.

On March 23, 2015, Anavex announced promising new preclinical data for both ANAVEX 2-73 and ANAVEX 3-71 (formerly AF710B), which was unveiled in two separate presentations at the 12th International Conference on Alzheimer's and Parkinson's Diseases and Related Neurological Disorders (AD/PD 2015) in Nice, France.

On March 17, 2015, Dr. Missling presented at 'The Physiopathology of Sigma-1 Receptors' symposium held at the Nice Sophia Antipolis University in Nice, France. His presentation, entitled 'Clinical trial design for Sigma-1 Receptor agonists,' included an overview of the Phase 2a clinical trial design of ANAVEX 2-73 and ANAVEX PLUS, which is ongoing in Alzheimer's patients.

On March 12, 2015, Anavex announced the appointment of Jacqueline French, MD, FAAN, to the Company's Scientific Advisory Board. An award-winning, internationally recognized expert on epilepsy, new therapeutic interventions and clinical trial methodology, Dr. French is Professor in the Department of Neurology at New York University (NYU), Co-Director of Epilepsy Research and Clinical Trials at NYU's Comprehensive Epilepsy Center and Director of the Epilepsy Study Consortium. 

On March 5, 2015, Anavex announced the appointment of Corinne Lasmezas, DVM, PhD, to the Company's Scientific Advisory Board.  A professor at The Scripps Research Institute for the past 10 years, Dr. Lasmézas is internationally recognized in the field of neurogenerative diseases with a focus now on studying the mechanisms of neurodegeneration.

On February 25, 2015, Anavex announced the findings of a research report in the current issue of peer-reviewed scientific journal Frontiers in Cellular Neuroscience . Among its conclusions, the report revealed that ANAVEX 2-73 prevents mitochondrial dysfunction and blocks resulting oxidative stress and apoptosis (cell death) in a nontransgenic mouse model of Alzheimer's disease. By preserving mitochondrial functionality and reducing other key AD hallmarks, Anavex said, its drug candidate ANAVEX 2-73 has the potential to prevent, stop, slow or reverse the disease, in addition to treating its symptoms.

The financial information for the three and six months ended March 31, 2015 should be read in conjunction with the Company's interim consolidated financial statements, which have been filed on U.S. Securities and Exchange Commission's EDGAR system and will be available on the Anavex website at www.anavex.com .

About Anavex Life Sciences Corp.

Anavex Life Sciences Corp. (OTCQX:AVXL) is a publicly traded biopharmaceutical company dedicated to the development of novel drug candidates to treat central nervous system (CNS) diseases, pain and various types of cancer. The Company's lead drug candidates, ANAVEX 2-73 and ANAVEX PLUS, the combination of ANAVEX 2-73 and donepezil (Aricept®), are currently being evaluated in a Phase 2a clinical trial for Alzheimer's disease. ANAVEX 2-73 is an orally available drug candidate that targets sigma-1 and muscarinic receptors and has successfully completed a Phase 1 study with a clean data profile. Preclinical studies demonstrate its potential to halt and/or reverse the course of Alzheimer's disease. The drug combination, ANAVEX PLUS, produced up to 80% greater reversal of memory loss in Alzheimer's disease models versus when the drugs were used individually. Recent positive preclinical data indicates that ANAVEX 2-73 also exhibits anticonvulsant, anti-amnesic, neuroprotective and anti-depressant properties, indicating its potential to treat additional CNS disorders, including epilepsy and others. Further information is available at www.anavex.com .

Forward-Looking Statements

Statements in this press release that are not strictly historical in nature are forward-looking statements. These statements are only predictions based on current information and expectations and involve a number of risks and uncertainties. Actual events or results may differ materially from those projected in any of such statements due to various factors, including the risks set forth in the Company's most recent Annual Report on Form 10-K filed with the SEC. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement and Anavex Life Sciences Corp. undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof.

     
ANAVEX LIFE SCIENCES CORP.
CONSOLIDATED BALANCE SHEETS
     
ASSETS
     
  March 31, September 30,
  2015 2014
Current    
Cash  $ 6,310,643  $ 7,262,138
Prepaid expenses  51,985  89,117
Total current assets  6,362,628  7,351,255
Equipment  1,749  2,247
Total assets  $ 6,364,377  $ 7,353,502
     
LIABILITIES AND STOCKHOLDERS' EQUITY
     
Current    
Accounts payable and accrued liabilities  $ 1,437,939  $ 1,249,084
Promissory notes payable  90,412  192,065
Total current liabilities  1,528,351  1,441,149
Non-interest bearing liabilities  133,727  5,719,727
Total liabilities  1,662,078  7,160,876
Common stock  64,876  47,201
Additional paid-in capital  59,082,325  52,078,750
Common stock to be issued  640,000  640,000
Accumulated deficit  (55,084,902)  (52,573,325)
Total stockholders' equity (capital deficit)  4,702,299  192,626
Total liabilities and stockholders' equity  $ 6,364,377  $ 7,353,502
     
ANAVEX LIFE SCIENCES CORP.
INTERIM STATEMENTS OF OPERATIONS
THREE MONTHS ENDED MARCH 31, 2015
     
  2015 2014
     
OPERATING EXPENSES    
Research and development  $ 407,146  $ 118,152
General and administrative  451,193  903,015
Total operating expenses  858,339  1,021,167
     
OPERATING LOSS  (858,339)  (1,021,167)
     
OTHER INCOME    
Interest and finance expenses, net  2,228  (5,079)
Financing related charges and adjustments  (912,357)  (1,011)
Foreign exchange loss  43,609  8,397
Total other income  (866,520)  2,307
     
NET LOSS  $ (1,724,859)  $ (1,018,860)
     
NET LOSS PER COMMON SHARE    
BASIC  $ (0.03)  $ (0.03)
DILUTED  $ (0.03)  $ (0.03)
     
WEIGHTED AVERAGE NUMBER OF SHARES OUTSTANDING  
BASIC   57,307,779  37,881,209
DILUTED  57,307,779  37,881,209
     
ANAVEX LIFE SCIENCES CORP.
INTERIM STATEMENTS OF OPERATIONS
SIX MONTHS ENDED MARCH 31, 2015
     
  2015 2014
     
OPERATING EXPENSES    
Research and development  $ 725,771  $ 123,332
General and administrative  903,246  1,207,443
Total operating expenses  1,629,017  1,330,775
     
OPERATING LOSS (1,629,017) (1,330,775)
     
OTHER INCOME    
Interest and finance expenses, net  (74,781)  (8,366)
Financing related charges and adjustments  (874,706)  681,989
Foreign exchange loss  66,927  (3,071)
Total other income  (882,560)  670,552
     
NET LOSS $ (2,511,577) $ (660,223)
     
NET LOSS PER COMMON SHARE    
BASIC  $ (0.05)  $ (0.02)
DILUTED  $ (0.05)  $ (0.04)
     
WEIGHTED AVERAGE NUMBER OF SHARES OUTSTANDING    
BASIC   54,437,890  37,680,823
DILUTED  54,437,890  37,680,823

Anavex Life Sciences Corp. Research & Business Development Toll-free: 1-844-689-3939 Email: Shareholder & Media Relations Toll-free: 1-866-505-2895 Outside North America: +1 (416) 489-0092 Email: www.anavex.com

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Layne’s Jacksonville Debut Tests East Texas Expansion

Updated Category News Views 57

Jacksonville is not some flashy coastal launch, and that is precisely why this Layne’s Chicken Fingers opening matters. A new chicken tender shop at 1217 S. Jackson St. will not move public markets, because this is a franchise-growth story rather than a ticker story. But it does offer a clean look at whether Layne’s can turn its Texas roots into a durable multi-market...

Continue Reading
Health In Tech Brings a Tech Veteran Onto Its Board

Updated Category News Views 115

Board appointments rarely make the cash register ring, but they can tell you where management thinks the next bruises are coming from. Health In Tech has added Tim Cortes as an independent director, put him in charge of the Compensation Committee, and placed him on both the Audit and Nominating and Corporate Governance Committees. For an AI-enabled insurance technology...

Continue Reading
Hisense Year-End Push Tests Its Connected-Home Pitch

Updated Category News Views 98

A 300-inch picture is one heck of a way to sell a refrigerator. Hisense is rolling out year-end offers across the Middle East and Africa that stitch together its premium displays, connected appliances and ConnectLife software under one big household-upgrade pitch. It is glossy stuff, sure, but there is a practical commercial question underneath all the sparkle: can the...

Continue Reading
Veterans United Foundation Marks 15 Years of Giving

Updated Category News Views 62

A Milestone Measured in More Than Checks Fifteen years can turn a workplace charity into background noise, but this one plainly has not drifted into autopilot. Veterans United Foundation closed its 2026 anniversary campaign, called The Good Goes On, with $1.5 million directed to charitable organizations, 1,145 employee volunteers, and 2,680 hours of hands-on work. That is...

Continue Reading
Sectra's RSNA AI Pitch Centers on Workflow, Not Hype

Updated Category News Views 294

Radiology has heard enough grand AI promises to fill a hospital basement, which makes Sectra's RSNA 2026 message refreshingly grounded. The Swedish imaging IT and cybersecurity company is putting its weight behind the unglamorous part of adoption: fitting AI into the daily diagnostic machinery without handing clinicians another awkward system to babysit. That is where...

Continue Reading
Specialty Chemicals Need Demand Before Capacity Bets

Updated Category News Views 96

Empty reactor space does not get filled because everybody suddenly loves reshoring. SOCMA's 2027 Contract Manufacturing Outlook makes that stubborn fact hard to dodge: nearly 70% of surveyed respondents expect North American manufacturing activity to rise over the next three years, yet 79.5% say stronger, more predictable customer demand is critical before future...

Continue Reading
BD&J's Workplace Recognition Meets Los Angeles Growth Test

Updated Category News Views 82

A workplace award is not a verdict from a jury, but it can still tell you where a law firm is putting its money and attention. BD&J Injury Lawyers landed on the Los Angeles Business Journal's 2026 list of most admired law firms to work for, announced November 18. For a personal-injury practice trying to deepen its footing in a brutally crowded Los Angeles market, that is...

Continue Reading
APEC in Shenzhen Puts Trade Openness Back in Focus

Updated Category News Views 11

Shenzhen is hosting a familiar but consequential argument: prosperity gets harder to share when trade channels clog up. At the 33rd Asia-Pacific Economic Cooperation Economic Leaders' Meeting on November 18, President Xi Jinping used the opening of the APEC CEO Summit to argue for peace, openness, innovation, mutual benefit and support for the WTO-centered multilateral...

Continue Reading
Sysco's Northern California Labor Deal Gets Bigger

Updated Category News Views 94

One hundred forty-four drivers may not rattle a giant food distributor by themselves, but labor agreements have a habit of growing legs. Sysco's Northern California and Nevada regional contract has added members from Teamsters Locals 386 and 431, bringing its coverage above 1,100 workers. For investors watching Sysco, this is less about one afternoon's headline and more...

Continue Reading
Volta M100 Puts Flexibility at Pad Printing's Center

Updated Category News Views 78

A tabletop printer rarely earns a second glance, but the Volta M100 is making a sensible argument: small manufacturers do not need another rigid box that becomes obsolete the minute a job changes. Boston Industrial Solutions has introduced the Volta M100 as a pad-printing machine built around adjustability, operator convenience, and software that can be upgraded as...

Continue Reading

Top 5 Most Recently Viewed Articles

NACON Introduces Exciting New Products at Gamescom 2024

Updated Category News Views 171

NACON Showcases Exciting New Products at Gamescom 2024 As the buzz around Gamescom reaches its peak, NACON is excited to unveil its latest products. This year, they are introducing a range of new accessories, including the Revolution X Unlimited, a wireless controller officially licensed for Xbox. Additionally, NACON is presenting a fresh lineup of games, featuring two...

Continue Reading
Nokia Partners with DE-CIX to Enhance New York's IX Infrastructure

Updated Category News Views 151

Nokia Partners with DE-CIX for Internet Exchange Upgrade Nokia has entered into an exciting partnership with DE-CIX, the world’s premier Internet Exchange operator, to enhance the backbone network for New York's largest Internet Exchange. This upgrade utilizes cutting-edge technologies aimed at providing improved network performance and operational efficiency. Upgrade...

Continue Reading
Celsior Unveils New Digital Hub to Elevate Tech Solutions

Updated Category News Views 221

Celsior Unveils New Digital Hub Celsior, the Solutions Delivery division of Pyramid IT Consulting, has made an exciting announcement regarding the launch of its new digital delivery center. This significant development will enhance digital transformation for key industries, marking a pivotal moment in the company’s journey. Strategic Expansion in India With nearly three...

Continue Reading
Teamworks Secures $235 Million to Propel AI Innovations in Sports

Updated Category News Views 510

Teamworks Secures $235 Million to Propel AI Innovations Oversubscribed Series F Financing Led by Dragoneer Investment Group Teamworks, known as the Operating System for Sports™, has made headlines by successfully raising $235 million in an oversubscribed Series F financing round, led by the prominent Dragoneer Investment Group. This funding round has placed the...

Continue Reading
Kaiser Aluminum Corporation Welcomes New Leadership Team

Updated Category News Views 517

Kaiser Aluminum Corporation Welcomes New Leadership Team Kaiser Aluminum Corporation (NASDAQ: KALU) is proud to announce significant leadership changes in its Board of Directors, heralding a new chapter for the company. This transition follows the retirement of Jack A. Hockema, who has served as Executive Chair of the Board for nearly three decades. Effective immediately,...

Continue Reading